secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0000950170-25-096656
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025
--------------------------------------------------------------------------------

- Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.
- Jerman replaces Holger Weis on committees after Weis became CEO; Jerman will chair Audit Committee.
- Compensation: $40k annual cash retainer, plus committee fees; initial option for 10,000 shares vesting over 36 months.
- Prorated annual grant of 3,200 shares awarded; vesting subject to continued service through 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/0000950170-25-096656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/tcrt-20250715.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-096656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer